Co-treatment with BBR (50 mg/kg) significantly reduced CPS-induced kidney damage, as demonstrated by lower serum urea, creatinine, uric acid, cystatin C and NGAL levels by 33 %, 48 %, 44 %, 55 % and 56 % respectively, compared to the CPS-alone group. This evidence concerns the gene LCN2 and Nephropathy.